摘要
目的 了解我院产超广谱 β 内酰胺酶菌株的耐药情况。 方法 用纸片扩散法检测了 10 0株产超广谱β 内酰胺酶的大肠埃希菌和肺炎克雷伯菌对 16种抗生素的耐药性。 结果 6 6株产ESBLs的大肠埃希菌对 16种抗生素的敏感性排在前三位的是 :亚胺培南 (10 0 % ) ,头孢哌酮 /舒巴坦 (10 0 % ) ,哌拉西林 /他唑巴坦 (94 .1% ) ;34株产ESBLs肺炎克雷伯菌对 16种抗生素的敏感性排在前三位的是 :亚胺培南 (97.0 % ) ,哌拉西林 /他唑巴坦(84 .6 % ) ,头孢吡肟 (73.7% )。结论 治疗产ESBLs大肠埃希菌引起的感染的首选药物为亚胺培南和头孢哌酮 /舒巴坦 ,其次为哌拉西林 /他唑巴坦 ;治疗产ESBLs肺炎克雷伯菌引起的感染的首选药物是亚胺培南 ,其次是哌拉西林 /他唑巴坦 ;
Objective To investigate the antibiotic resistance of clinical isolates that produced extended spectrum β lactamases(ESBLs) in our hospital. Methods Antibiotic susceptibilities of 100 ESBL producing strains of Escherichia coli and Klebsiella pneumoniae were determined by Kirby Bauer test. Results The first three susceptible antimicrobial drugs for the 66 strains of Escherichia coli were imipenem ( 100% ), cefoperazone/sulbactam ( 100% ) and piperacillin/tazobactam ( 94.1% ); the first three susceptible antimicrobial durgs for 34 strains of Klebsiella pneumoniae were imipenem ( 97.0% ), piperacillin/tazobactam ( 84.6% ) and cefepime ( 73.7% ). Conclusion Imipenem and cefoperazone/sulbactam are the best drug for treatment of ESBL producing Escherichia coli, the next is piperacillin/tazobactam. As for Klebsiella pneumoniae, imipenem is the best one, the next is piperacillin/tazobactam. The antibiotic susceptibility of Klebsiella pneumoniae is generally lower than that of Escherichia coli.
出处
《中国感染控制杂志》
CAS
2003年第1期22-24,共3页
Chinese Journal of Infection Control
关键词
超广谱β—内酰胺酶菌株
药敏试验
结果比较
亚胺培南
头孢哌酮
舒巴坦
extended spectrum β lactamase
antibiotic resistance
Escherichia coli
Klebsiella pneumoniae [Chin J Infect Control, 2003, 2(1): 22-24]
